Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2023 16:01 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company...
November 06, 2023 07:30 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company...
November 02, 2023 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference

CHARLOTTESVILLE, Va., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
October 27, 2023 09:25 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease

- Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to inform dose selection, plus further analyses of...
October 04, 2023 08:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)

Expanded analyses from robust Phase 1 INTERCEPT-AD trial exploring novel target engagement (dose-related), amyloid plaque reduction, and ARIA levels observed with ACU193 administration to be included...
September 19, 2023 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that...
September 06, 2023 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference

CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that...
August 08, 2023 07:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights

Positive INTERCEPT-AD Phase 1 trial results announced in July 2023 demonstrate ACU193’s potential as a differentiated antibody for the treatment of early Alzheimer’s diseaseCash, cash equivalents and...
August 01, 2023 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company...
July 18, 2023 22:31 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Announces Pricing of Upsized $130 Million Public Offering

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 18, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen”) (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel...